Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Drug

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment

Fineline Cube Jul 4, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...

Company Drug

Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301

Fineline Cube Jul 4, 2025

Chinese partners Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) and Space Peptides jointly announced the...

Company Deals

CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector

Fineline Cube Jul 4, 2025

China Resources Medical Holdings Company Limited has entered into a strategic partnership with Shanghai Haohai...

Company Deals Drug

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China

Fineline Cube Jul 4, 2025

China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...

Company Deals

AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange

Fineline Cube Jul 3, 2025

AstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot is exploring plans to move the British pharmaceutical...

Company Drug

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11

Fineline Cube Jul 3, 2025

China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...

Company Drug

Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC

Fineline Cube Jul 3, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that the U.S. Food and Drug Administration...

Company Drug

Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing

Fineline Cube Jul 3, 2025

French firm Servier Pharmaceutical plc.’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)...

Company Drug

Sichuan Biokin’s Iza-bren Meets Primary Endpoint in Phase III NPC Trial

Fineline Cube Jul 3, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its Phase III clinical study...

Company Drug

Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma

Fineline Cube Jul 3, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...

Company Drug

Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 3, 2025

China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...

Company Drug

China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment

Fineline Cube Jul 3, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...

Company Deals

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain

Fineline Cube Jul 3, 2025

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) this week entered into a technology...

Company Drug

AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion

Fineline Cube Jul 3, 2025

US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...

Company Drug

Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis

Fineline Cube Jul 3, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...

Company Deals

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics

Fineline Cube Jul 3, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...

Company Drug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

Fineline Cube Jul 3, 2025

China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...

Company Drug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Fineline Cube Jul 3, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors

Fineline Cube Jul 2, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...

Company Drug

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC

Fineline Cube Jul 2, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...

Posts pagination

1 … 180 181 182 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.